Findings

What do systematic reviews say?

10 questions · 10 findings · 3 reviews · Infectious Diseases · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 10%Low 5 · 50%Moderate 2 · 20%High 2 · 20%

Vitamin D vs placebo

CD4 cell count · adults with HIV infection

1 finding from 1 review

Micronutrient supplementation in adults with HIV infection 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 288 participants
Low

Zinc vs placebo

Change in CD4 count · adults with HIV infection

1 finding from 1 review

Micronutrient supplementation in adults with HIV infection 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 431 participants
Low

Selenium vs placebo

Change in CD4 count · adults with HIV infection

1 finding from 1 review

Micronutrient supplementation in adults with HIV infection 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1187 participants
Low

Vitamin A vs placebo

CD4 cell count · adults with HIV infection

1 finding from 1 review

Micronutrient supplementation in adults with HIV infection 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 464 participants
Low

Intervention not reported

HIV RNA levels less than 50 cells/mL · HIV‐positive adults

The intervention showed no clear difference in HIV RNA levels less than 50 cells/mL (high certainty).

1 finding from 1 review

Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults 2017 · Cochrane Headline outcomes only
RR 0.97 [0.81, 1.15]
5 studies · 805 participants
High

Intervention not reported

HIV RNA levels less than 500 cells/mL · HIV‐positive adults

The intervention showed no clear difference in HIV RNA levels less than 500 cells/mL (high certainty).

1 finding from 1 review

Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults 2017 · Cochrane Headline outcomes only
RR 0.96 [0.82, 1.12]
4 studies · 5929 participants
High

Intervention not reported

All‐cause mortality · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Chemotherapy for second‐stage human African trypanosomiasis: drugs in use 2021 · Cochrane Headline outcomes only
RR 2.22 [0.49, 10.11]
1 study · 394 participants
Low

Intervention not reported

Relapsec · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…

The intervention probably leads to higher relapsec (moderate certainty).

1 finding from 1 review

Chemotherapy for second‐stage human African trypanosomiasis: drugs in use 2021 · Cochrane Headline outcomes only
RD 0.05 [0.02, 0.08]
1 study · 394 participants
Moderate

Intervention not reported

Serious adverse events · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…

It is very uncertain whether the intervention changes serious adverse events (very low certainty).

1 finding from 1 review

Chemotherapy for second‐stage human African trypanosomiasis: drugs in use 2021 · Cochrane Headline outcomes only
RR 1.17 [0.64, 2.17]
1 study · 394 participants
Very low

Intervention not reported

Adverse events · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…

The intervention showed no clear difference in adverse events (moderate certainty).

1 finding from 1 review

Chemotherapy for second‐stage human African trypanosomiasis: drugs in use 2021 · Cochrane Headline outcomes only
RR 1.01 [0.95, 1.06]
1 study · 394 participants
Moderate